Table 3.

Univariate log-rank test analysis of factors associated with survival in 19 patients with PEL treated with modified EPOCH

VariableP
Platelets (above vs below median) .10 
Hemoglobin (above vs below median) .24 
Albumin (above vs below median) .64 
CRP (above vs below median) .99 
Ferritin (above vs below median) .054 
Lactate dehydrogenase (above vs below median) .15 
IgG (above vs below median) .21 
IgE (above vs below median) .019 
κ FLC (above vs below median) .87 
Λ FLC (above vs below median) .87 
CD4+ (above vs below median) .82 
HIV <100 copies/mL .71 
KSHV viral load (above vs below median) .51 
Tumor EBV status .029 
Clinical Kaposi sarcoma .61 
KSHV-MCD .39 
Previous doxorubicin/liposomal doxorubicin .63 
Rituximab with therapy .21 
Bevacizumab .84 
High-dose methotrexate .54 
Protease inhibitor–based antiretroviral regimen .30 
IL-6 (above vs below median) .013 
IL-8 (above vs below median) .60 
IL-10 (above vs below median) .041 
INF-γ (above vs below median) .37 
TNF-α (above vs below median) .26 
VariableP
Platelets (above vs below median) .10 
Hemoglobin (above vs below median) .24 
Albumin (above vs below median) .64 
CRP (above vs below median) .99 
Ferritin (above vs below median) .054 
Lactate dehydrogenase (above vs below median) .15 
IgG (above vs below median) .21 
IgE (above vs below median) .019 
κ FLC (above vs below median) .87 
Λ FLC (above vs below median) .87 
CD4+ (above vs below median) .82 
HIV <100 copies/mL .71 
KSHV viral load (above vs below median) .51 
Tumor EBV status .029 
Clinical Kaposi sarcoma .61 
KSHV-MCD .39 
Previous doxorubicin/liposomal doxorubicin .63 
Rituximab with therapy .21 
Bevacizumab .84 
High-dose methotrexate .54 
Protease inhibitor–based antiretroviral regimen .30 
IL-6 (above vs below median) .013 
IL-8 (above vs below median) .60 
IL-10 (above vs below median) .041 
INF-γ (above vs below median) .37 
TNF-α (above vs below median) .26 

or Create an Account

Close Modal
Close Modal